Why the study?
Does dapagliflozin reduce the incidence of reported episodes of AF/AFL adverse events in high-risk patients with type 2 diabetes mellitus?
Does dapagliflozin reduce the incidence of reported episodes of AF/AFL adverse events in high-risk patients with type 2 diabetes mellitus?
Dapagliflozin reduces the incidence of atrial fibrillation and atrial flutter adverse events in high-risk patients with type 2 diabetes mellitus.
May reduce AF/AFL events in high-risk T2DM; hypothesis-generating and requires dedicated prospective confirmation before practice change.
Dapagliflozin decreased the incidence of reported episodes of AF/AFL adverse events in high-risk patients with type 2 diabetes mellitus. This effect was consistent regardless of the patient's previous history of AF, atherosclerotic cardiovascular disease, or HF. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01730534.
No takes yet. Share an insight, caveat, or question.
Zelniker et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: